AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25011384 — intervention group
Group type: COMPARATOR
Intervention: All exercise modes
Number of subjects: 110
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) cohort
Number of subjects: 37049
Study 23020192 — intervention group
Group type: COMPARATOR
Intervention: Non-CKD cohort
Number of subjects: 37049
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD cohort
Number of subjects: 37049
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD cohort (elderly)
Number of subjects: 37049
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD cohort (youngest group)
Number of subjects: 37049
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD cohort with alcoholism
Number of subjects: 37049
Study 23020192 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD cohort taking benzodiazepines
Number of subjects: 37049
Study 19190821 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype Gly16-Gln27-Thr164
Number of subjects: 25224
Study 19190821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25224
Study 16720159 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 143
Study 16720159 — intervention group
Group type: COMPARATOR
Intervention: Surgery first
Number of subjects: 143
Study 15158621 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment
Number of subjects: 22
Study 11563205 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home assessment with individualized treatment plan including exercise program
Number of subjects: 163
Study 11563205 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 163
Study 11563205 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home assessment with individualized treatment plan including exercise program (for subjects with more than 2 falls in the 3 months preceding study entry)
Number of subjects: 163
Study 9756110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ)
Number of subjects: 34
Study 9756110 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylclozapine (DMCLZ)
Number of subjects: 34
Study 9756110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine/Desmethylclozapine ratio in plasma
Number of subjects: 34
Study 9756110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine/Desmethylclozapine ratio in saliva
Number of subjects: 34
Study 9756110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ) and Desmethylclozapine (DMCLZ) saliva concentrations
Number of subjects: 34
Study 7529693 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) 75 units
Number of subjects: 19
Study 7529693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3043949 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoconazole cream, solution, and spray (once or twice daily)
Number of subjects: 372
Study 31271072 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 9
Study 31271072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein hydrolysate (FPH)
Number of subjects: 9
Study 31271072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 31641001 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-informed resiliency class (B-RICH+)
Number of subjects: 100
Study 31641001 — intervention group
Group type: COMPARATOR
Intervention: Depression QI alone
Number of subjects: 100
Study 27670154 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of cholecalciferol (400 IU)
Number of subjects: 70
Study 27670154 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose cholecalciferol (50,000 IU)
Number of subjects: 70
Study 25548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention programme with regular check-ups and a coaching approach
Number of subjects: 15
Study 25548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led approach with personal relationship and coaching
Number of subjects: 15
Study 25548315 — intervention group
Group type: COMPARATOR
Intervention: General preventive advice
Number of subjects: 15
Study 25548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical support
Number of subjects: 15
Study 23616547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluations in the social domain
Number of subjects: 27
Study 23616547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluations in the academic domain
Number of subjects: 27
Study 21477053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex under the influence of drugs or alcohol
Number of subjects: 37
Study 21477053 — intervention group
Group type: COMPARATOR
Intervention: No influence of drugs or alcohol
Number of subjects: 37
Study 19055791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) morning dose at 8:00
Number of subjects: 81
Study 19055791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) pre-dinner dose at 17:00
Number of subjects: 81
Study 19055791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) evening dose at 22:00
Number of subjects: 81
Study 19055791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 16769438 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer-Assisted Self-Interview (ACASI)
Number of subjects: 268
Study 16769438 — intervention group
Group type: COMPARATOR
Intervention: Interviewer‐Administered Questionnaire (IAQ)
Number of subjects: 268
Study 15612863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of suicide intent
Number of subjects: 180
Study 15612863 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate expectations about the likelihood of dying
Number of subjects: 180
Study 15612863 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of suicide intent
Number of subjects: 180
Study 11887831 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy and SERMs (raloxifene)
Number of subjects: 0
Study 11887831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 0
Study 11887831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 9228376 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (7 to 11 hours postoperatively) - Group A (201 patients)
Number of subjects: 404
Study 9228376 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation (between 8 and 12 AM the following day) - Group B (203 patients)
Number of subjects: 404
Study 9228376 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation - Group A
Number of subjects: 404
Study 9228376 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation - Group B
Number of subjects: 404
Study 8077324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low insulin infusion (742 +/- 212 pmol/L)
Number of subjects: 7
Study 8077324 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin infusion (3360 +/- 710 pmol/L)
Number of subjects: 7
Study 8077324 — intervention group
Group type: COMPARATOR
Intervention: Both insulin infusions
Number of subjects: 7
Study 3608350 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 5 mg
Number of subjects: 8
Study 3608350 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 10 mg
Number of subjects: 8
Study 3608350 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 8
Study 3608350 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 8
Study 3608350 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (intermediate dose between 10 and 20 mg)
Number of subjects: 8
Study 3608350 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid pretreatment with Torasemide 20 mg
Number of subjects: 8
Study 30299202 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC qw monotherapy
Number of subjects: 0
Study 28695373 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation with an additional linear lesion at the roof of the left atrium (group A)
Number of subjects: 250
Study 28695373 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation without an additional linear lesion at the roof of the left atrium (group B)
Number of subjects: 250
Study 24325547 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nonfunctional loading
Number of subjects: 21
Study 24325547 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading (control)
Number of subjects: 21
Study 23701202 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of CQ (600 mg on days 1-2, 300 mg on day 3) and TQ (450 mg on days 2 and 3)
Number of subjects: 0
Study 23701202 — intervention group
Group type: COMPARATOR
Intervention: TQ alone (450 mg on days 2 and 3)
Number of subjects: 0
Study 23701202 — intervention group
Group type: COMPARATOR
Intervention: CQ alone (600 mg on days 1-2, 300 mg on day 3)
Number of subjects: 0
Study 21778609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐UV: UV irradiation from a distance of 10 cm for 10 min
Number of subjects: 12
Study 21778609 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐UV: UV irradiation from a distance of 1 cm for 3 min
Number of subjects: 12
Study 21778609 — intervention group
Group type: COMPARATOR
Intervention: Control: No surface treatment
Number of subjects: 12
Study 19712032 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing by the AUT
Number of subjects: 784
Study 19712032 — intervention group
Group type: COMPARATOR
Intervention: Control group (indication‐based guidelines for prescription of broad‐spectrum antimicrobials)
Number of subjects: 784
Study 19712032 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from the AUT alone
Number of subjects: 784
Study 19712032 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from both the AUT and the infectious diseases consultation service
Number of subjects: 784
Study 16542207 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol sustained release every 12 h for 12 weeks
Number of subjects: 76
Study 16542207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15145633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (single dose of about 10 mg/kg)
Number of subjects: 144
Study 15145633 — intervention group
Group type: COMPARATOR
Intervention: Parenteral quinine (10 mg/kg at 0, 4, and 12 h)
Number of subjects: 144
Study 15145633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate and parenteral quinine
Number of subjects: 144
Study 11180036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg) coadministration with Sirolimus (10 mg)
Number of subjects: 18
Study 11180036 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (10 mg) alone
Number of subjects: 18
Study 11180036 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (120 mg) alone
Number of subjects: 18
Study 9597123 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra treatment for six months
Number of subjects: 0
Study 9597123 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human IL-1Ra
Number of subjects: 0
Study 8199179 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat-enriched (Poly) diet
Number of subjects: 8
Study 8199179 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 diet
Number of subjects: 8
Study 8199179 — intervention group
Group type: COMPARATOR
Intervention: Average American diet (AAD)
Number of subjects: 8
Study 8199179 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 diet and Poly diet (Study B)
Number of subjects: 8
Study 8199179 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial lipid and lipoprotein concentrations
Number of subjects: 8
Study 2452393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemo‐radiotherapy (2 x COPP + ABVD + 20 Gy EF)
Number of subjects: 373
Study 2452393 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 x COPP + ABVD)
Number of subjects: 373
Study 2452393 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (3 x COPP + ABVD) with consolidation by radiotherapy (20 Gy IF)
Number of subjects: 373
Study 2452393 — intervention group
Group type: EXPERIMENTAL
Intervention: Including salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 x CEVD in case of persisting disseminated disease)
Number of subjects: 373
Study 28642211 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component care model combining collaborative care, decision-support, and population health management.
Number of subjects: 404
Study 28642211 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 404
Study 28642211 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component care model.
Number of subjects: 404
Study 25550338 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate monotherapy followed by add-on therapy with sulfasalazine and hydroxychloroquine
Number of subjects: 316
Study 25550338 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate monotherapy followed by add-on therapy with infliximab
Number of subjects: 316
Study 25550338 — intervention group
Group type: EXPERIMENTAL
Intervention: initial methotrexate therapy
Number of subjects: 316
Study 25550338 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CCP antibodies
Number of subjects: 316
Study 25550338 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-cVim antibodies
Number of subjects: 316
Study 25462702 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiss® fibrin glue plus drainage
Number of subjects: 60
Study 25462702 — intervention group
Group type: COMPARATOR
Intervention: Control (drainage alone)
Number of subjects: 60
Study 21720885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise in the ipsilateral arm (n = 7)
Number of subjects: 15
Study 21720885 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise in the contralateral arm (n = 8)
Number of subjects: 15
Study 19615804 — intervention group
Group type: EXPERIMENTAL
Intervention: AST‐120 (6 g/d)
Number of subjects: 460
Study 19615804 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-protein diet and antihypertensive medication)
Number of subjects: 460
Study 17714419 — intervention group
Group type: EXPERIMENTAL
Intervention: Full applied tension (AT) procedure
Number of subjects: 1209
Study 17714419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body tension
Number of subjects: 1209
Study 17714419 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body tension
Number of subjects: 1209
Study 17714419 — intervention group
Group type: COMPARATOR
Intervention: Donation as usual (control group)
Number of subjects: 1209
Study 15131439 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental discography
Number of subjects: 50
Study 15131439 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric profiles
Number of subjects: 50
Study 15131439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not undergoing discography)
Number of subjects: 50
Study 15131439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset with somatization disorder in injection group
Number of subjects: 50
Study 11741827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO(2) for 3 h with intermittent moderate exercise
Number of subjects: 21
Study 11741827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO(2) for 3 h with intermittent moderate exercise
Number of subjects: 21
Study 11741827 — intervention group
Group type: EXPERIMENTAL
Intervention: NO(2) exposure
Number of subjects: 21
Study 11741827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO(2) exposure
Number of subjects: 21
Study 9818106 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg ropivacaine
Number of subjects: 52
Study 9818106 — intervention group
Group type: EXPERIMENTAL
Intervention: 187.5 mg ropivacaine
Number of subjects: 52
Study 9818106 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ropivacaine
Number of subjects: 52
Study 9818106 — intervention group
Group type: COMPARATOR
Intervention: 125 mg bupivacaine
Number of subjects: 52
Study 7576417 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental designs (regression-discontinuity design and multiple interrupted time-series design)
Number of subjects: 0
Study 7576417 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized experiments
Number of subjects: 0
Study 7576417 — intervention group
Group type: COMPARATOR
Intervention: Nonequivalent group designs
Number of subjects: 0
Study 7576417 — intervention group
Group type: COMPARATOR
Intervention: Pre-experimental research
Number of subjects: 0
Study 2651190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after dinner
Number of subjects: 304
Study 2651190 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 304
Study 319143 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol (Th1165a)
Number of subjects: 28
Study 319143 — intervention group
Group type: COMPARATOR
Intervention: ephedrine
Number of subjects: 28
Study 30852011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat CMR
Number of subjects: 60
Study 30852011 — intervention group
Group type: COMPARATOR
Intervention: High-lactose CMR
Number of subjects: 60
Study 28937830 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg per day for 2 months)
Number of subjects: 50
Study 28937830 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 50
Study 26561628 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 472
Study 26561628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 polyunsaturated fatty acids (1.2 g/d)
Number of subjects: 472
Study 26561628 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet (control)
Number of subjects: 472
Study 26561628 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 472
Study 23832463 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Number of subjects: 900
Study 23832463 — intervention group
Group type: COMPARATOR
Intervention: 18000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Number of subjects: 900
Study 21742107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean BMI during follow-up years (between-person BMI)
Number of subjects: 0
Study 21742107 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing BMI (within-person BMI change)
Number of subjects: 0
Study 21742107 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing BMI
Number of subjects: 0
Study 21742107 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 0
Study 21742107 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 0
Study 19349313 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (21- or 35-mg) nicotine patch
Number of subjects: 19
Study 19349313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16912031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 37
Study 16912031 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 37
Study 14872417 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa)
Number of subjects: 0
Study 11423598 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 66
Study 11423598 — intervention group
Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 66
Study 9413736 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (45 mg)
Number of subjects: 0
Study 9413736 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 7741805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vecuronium (0.3 mg kg ‐1)
Number of subjects: 50
Study 7741805 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium (1.0 mg kg ‐1)
Number of subjects: 50
Study 3948472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 hours before HCTZ
Number of subjects: 10
Study 3948472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 hours after HCTZ
Number of subjects: 10
Study 3948472 — intervention group
Group type: COMPARATOR
Intervention: Control (no cholestyramine)
Number of subjects: 10
Study 3948472 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cholestyramine 4 hours after HCTZ
Number of subjects: 10
Study 3948472 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cholestyramine (-24, -12, and +4 hours after HCTZ)
Number of subjects: 10
Study 29396633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCEPT intervention
Number of subjects: 103
Study 29396633 — intervention group
Group type: COMPARATOR
Intervention: HEALTH control condition
Number of subjects: 103
Study 27384042 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT (photobiomodulation therapy using cluster light‐emitting diodes; 104 diodes; wavelength 660 and 850 nm; energy density 1.5 and 4.5 J/cm2; energy 60 J at each point; total energy delivered 600 J)
Number of subjects: 15
Study 27384042 — intervention group
Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 15
Study 25139338 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 6240
Study 25139338 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers with BMI ≤ 25 kg/m(2)
Number of subjects: 6240
Study 25139338 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 6240
Study 25139338 — intervention group
Group type: EXPERIMENTAL
Intervention: All smokers (current and former)
Number of subjects: 6240
Study 25139338 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 6240
Study 23131207 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg dose of hemagglutinin (HA) antigen
Number of subjects: 380
Study 23131207 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg dose of hemagglutinin (HA) antigen
Number of subjects: 380